Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs VCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCEL Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

VCEL Overall Winner 6-Pillar Tally: MESO 0 – 6 VCEL Matrix Metrics: MESO 1 – 9 VCEL

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas VCEL carries 35.6/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin).

  • Growth vs. Quality Trade-Off: VCEL earns the overall head-to-head edge with a stronger Unified Composite Score (35.6/100 SELL vs. MESO 34.6/100 SELL) and 0.30β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although VCEL compares more favorably head-to-head, both MESO (34.6/100 SELL) and VCEL (35.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 75.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs VCEL
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
VCEL NASDAQ Head-to-Head Winner
Vericel Corporation
Biological Products, (No Disgnostic Substances)
$57.27
+0.54% 1D
Market Cap $2.9B
TTM Revenue $324M
Forward P/E 60.5x
Beta / 30D Vol 0.30β · 74% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 75
RSI-14: 75.4 · SMA20: $48.04 · SMA50: $43.15

6-Pillar Scorecard Institutional Category Breakdown (MESO 0 – 6 VCEL)

Columns: Metric · MESO · VCEL
1. Valuation Multiples VCEL
Forward P/E N/M 60.5x
Trailing P/E N/M 90.3x
PEG Ratio N/M N/M
EV / Revenue 14.1x 9.0x
2. Growth & Scale VCEL
Revenue Growth (YoY) +390.7% +26.5%
Earnings Growth (YoY) +0.0% +170.0%
TTM Revenue (USD) $120M $324M
Market Cap $1.7B $2.9B
3. Profitability & Quality VCEL
Gross Margin 80.0% 74.5%
Operating Margin -42.6% 8.3%
Net Profit Margin -47.8% 10.3%
Return on Equity (ROE) -9.9% 9.4%
4. Balance Sheet & Cash Flow VCEL
Cash Generation (TTM) -$45M EBITDA $58M
Cash Flow Margin -37.1% EBITDA Mgn 17.9%
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $43M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCEL
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 76.8% (37th %ile) 44.1% (13th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat VCEL
OpEx & R&D Intensity N/A 66.2% of Rev ($215M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (1) vs VCEL (9)
Institutional Metric MESO VCEL Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.9B Larger Scale VCEL
Trailing P/E Ratio
Valuation
N/M 90.3x Lower Multiple VCEL
Forward P/E Ratio
Valuation
N/M 60.5x Lower Multiple VCEL
Revenue Growth (YoY)
Growth
+390.7% +26.5% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% 8.3% Higher Margin VCEL
Net Profit Margin
Profitability
-47.8% 10.3% Higher Margin VCEL
Return on Equity (ROE)
Capital Efficiency
-9.9% 9.4% Higher ROE VCEL
52-Week Range Position
Momentum
6% ($12–$22) 92% ($29–$60) Stronger Trend VCEL
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 0.30β · 74% Vol Lower Realized Risk VCEL
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 35.6 / 100 (SELL) Higher Composite VCEL
Trailing 12M Revenue (USD)
Operating Scale
$120M $324M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% 74.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · 9.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) $58M ($43M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VCEL +48.81 pp
MESO: -6.1% · VCEL: +42.71%
3M Horizon VCEL +54.58 pp
MESO: -25.19% · VCEL: +29.39%
6M Horizon VCEL +79.06 pp
MESO: -14.82% · VCEL: +64.24%
1Y Horizon VCEL +60.17 pp
MESO: -16.42% · VCEL: +43.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs VCEL. Trailing 12-month operating profitability (MESO -42.6% vs VCEL 8.3%) and valuation multiples (MESO N/M vs VCEL 60.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
VCEL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$324M
Gross Margin74.5%
Op. Margin8.3%
ROE / Fwd P/E9.4% · 60.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCEL SURGE
5d in phase · OBV ACCUMULATION
Current IV 44.1%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VCEL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($215M)
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs VCEL Key Questions & Quantitative Answers

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas VCEL carries 35.6/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin). Growth vs. Quality Trade-Off: VCEL earns the overall head-to-head edge with a stronger Unified Composite Score (35.6/100 SELL vs. MESO 34.6/100 SELL) and 0.30β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VCEL compares more favorably head-to-head, both MESO (34.6/100 SELL) and VCEL (35.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 75.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCEL leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with VCEL at +26.5% YoY revenue growth and +170.0% YoY earnings growth on $324M TTM revenue (74.5% gross margin, 8.3% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $324M for VCEL. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($215M) (0 disclosures) for VCEL.

VCEL screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas VCEL trades at 60.5x Forward P/E, 90.3x Trailing P/E, N/M PEG, and 9.0x EV/Revenue (17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus VCEL (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, VCEL carries 44.1% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.30β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.